bluebird bio, Inc. (BLUE)

10.23
0.22 2.20
NASDAQ
Prev Close 10.01
Open 10.07
Day Low/High 9.99 / 10.35
52 Wk Low/High 9.25 / 28.97
Volume 567.71K
Exchange NASDAQ
Shares Outstanding 70.11B
Market Cap 697.57M
P/E Ratio N/A
Div & Yield N.A. (N.A)
4 Stocks to Play In Today's Market

4 Stocks to Play In Today's Market

Always trade the environment that you find yourself in.

2 'Rules of the Road' for Biotech Investing

2 'Rules of the Road' for Biotech Investing

Follow these maxims and you should do well in this volatile sector.

Midday Report: Keurig Deal Boosts Peers; Energy Stocks Slump

Midday Report: Keurig Deal Boosts Peers; Energy Stocks Slump

Energy stocks were hammered and pulled benchmark indexes lower by midday Monday.

Bluebird Bio downgraded at BofA/Merrill

Another Biotech Sets Off More Selling

Another Biotech Sets Off More Selling

Market is feeling very jittery.

Market Has a Mood Swing to the Upside

Gloom is gone as likelihood of Fed rate hike fades.

Flow of Bad News Pours Over Market

Flow of Bad News Pours Over Market

Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.

Jim Cramer Bullish on Microsoft, Likes General Mills and WhiteWave

Jim Cramer Bullish on Microsoft, Likes General Mills and WhiteWave

Jim Cramer answers viewers questions from social media on the floor of the New York Stock Exchange.

Bluebird Bio upgraded at Morgan Stanley

China's Weak Again, But Market Soars Anyway

Gap up holds steady in big day of gains.

Ugly Friday Finishes Off Last Week's Hope

Signs of support on the S&P, but there is a lot of uncertainty.

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis S.A.

Mr. Market's Even Wilder Ride

Something major has changed in the market.

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.

Market's Not in the Mood to Move

Market's Not in the Mood to Move

Attention turns to earnings and away from Greece, Fed.

Strong Finish Is Key for Market

But there's still the problem of limited upside momentum.

Bit of a Bounce Brings Sigh of Relief

Uncertainty on Greece prevails, but it could have been worse.

Celgene on My Shopping List for a Pullback

Celgene on My Shopping List for a Pullback

I have about 25% in cash; if the market falls 5-10%, I'm in.

How Quickly Can the Market Bounce Back?

Today's selling was steady; question is how long it will persist.

Market Slips as Greece Remains Unresolved

Market Slips as Greece Remains Unresolved

Traders are getting tired of being held hostage.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

Looking Back to Go Forward

Looking Back to Go Forward

For Bluebird Bio and Esperion, the charts tell the whole story.

Bears Shouldn't Get Too Cocky

There's still plenty of action out there.

Playing BLUE and MOMO Into Earnings

Playing BLUE and MOMO Into Earnings

One in the hottest area of the market.

A Steady but Sloppy Day

Awaiting Yellen, but some churn wouldn't hurt.

Futures Still Higher

Market still looks like it will open up February with a minor rally based on premarket futures. ExxonMobil (XOM) reported results that beat on the bottom line slightly and just missed on revenue expectations. Stock is up premarket; let's see what de...

The Bears Are Armed

Many think the market is on the verge of a long-awaited correction.

Trading Had an Odd Feel

There just wasn't a high level of commitment to the market.

On Hold for the ECB

Meanwhile, we have Netflix and IBM to entertain us.